<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02313727</url>
  </required_header>
  <id_info>
    <org_study_id>0099-14-BNZ</org_study_id>
    <nct_id>NCT02313727</nct_id>
  </id_info>
  <brief_title>Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression</brief_title>
  <official_title>Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It will be a pilot, 2 year, prospective, randomized, double-blind, placebo-controlled (for
      pamidronate) study. All patients with AS will receive treatment with TNF inhibitor, while
      randomization will be performed for pamidronate versus placebo group. Primary outcome will be
      the rate of radiographic progression of AS, calculated after 24 months of combined treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be a pilot, 2 year, prospective, randomized, double-blind, placebo-controlled (for
      pamidronate) study. All patients with AS will receive treatment with tumor necrosis factor
      (TNF) inhibitor, as indicated by local guidelines. Randomization will be performed for
      pamidronate vs placebo group. Pamidronate will be prescribed as monthly intravenous infusion
      in the dose of 60 mg/month for the first 6 consecutive months of every study year. Primary
      outcome will be the rate of radiographic progression of ankylosing spondylitis (AS),
      calculated after 24 months of combined treatment. Clinical and laboratory disease parameters
      will serve as secondary outcomes. These outcomes as well as safety assessments will be
      performed on a monthly basis up to 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified stock ankylosing spondylitis spine (mSASS) score</measure>
    <time_frame>24 months</time_frame>
    <description>calculated by X-ray films of the spine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bath ankylosing spondylitis radiographic index (BASRI)</measure>
    <time_frame>24 months</time_frame>
    <description>calculated by X-ray films of the spine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bath ankylosing spondylitis disease activity index (BASDAI)</measure>
    <time_frame>monthly from the date of randomization up to 24 months</time_frame>
    <description>calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankylosing spondylitis disease activity index (ASDAS)</measure>
    <time_frame>monthly from the date of randomization up to 24 months</time_frame>
    <description>calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath ankylosing spondylitis functional index (BASFI)</measure>
    <time_frame>monthly from the date of randomization up to 24 months</time_frame>
    <description>calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath ankylosing spondylitis metrology index (BASMI)</measure>
    <time_frame>monthly from the date of randomization up to 24 months</time_frame>
    <description>calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>pamidronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pamidronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>intravenous infusion of pamidronate 60 mg</description>
    <arm_group_label>pamidronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (NaCl 0.9%)</intervention_name>
    <description>intravenous infusion of NaCl 0.9% 500 ml</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of spinal syndesmophytes

          -  normal renal and liver function

          -  eligibility to receive anti-TNF treatment according to local guidelines

        Exclusion Criteria:

          -  unwilling to sigh the informed consent

          -  presence of significant systemic or organ-limited disorders, other than AS

          -  any contraindication for anti-TNF or pamidronate treatment

          -  presence of acute dental/periodontal disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>38041</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Slobodin G, Rosner I, Feld J, Rimar D, Rozenbaum M, Boulman N, Odeh M. Pamidronate treatment in rheumatology practice: a comprehensive review. Clin Rheumatol. 2009 Dec;28(12):1359-64. doi: 10.1007/s10067-009-1256-2. Epub 2009 Aug 19. Review.</citation>
    <PMID>19690938</PMID>
  </reference>
  <reference>
    <citation>Slobodin G, Rosner I, Rimar D, Boulman N, Rozenbaum M, Odeh M. The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. Clin Rheumatol. 2010 Jul;29(7):793-4. doi: 10.1007/s10067-010-1378-6. Epub 2010 Jan 29.</citation>
    <PMID>20111975</PMID>
  </reference>
  <reference>
    <citation>Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20764-9. doi: 10.1073/pnas.0805133106. Epub 2008 Dec 15.</citation>
    <PMID>19075223</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

